Axsome Therapeutics (AXSM) Free Cash Flow (2015 - 2026)
Axsome Therapeutics (AXSM) reported Free Cash Flow of -$20.8 million for Q1 2026, up 52.37% on a YoY basis from -$13.7 million in Q1 2025, and down 11.2% sequentially from -$18.7 million in Q4 2025.
Axsome Therapeutics (AXSM) Free Cash Flow (2015 - 2026) Analysis & Trends
Axsome Therapeutics (AXSM) has 12 years of Free Cash Flow data on file, last reported at -$20.8 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 52.37% year-over-year to -$20.8 million; the trailing twelve-month figure through Mar 2026 stood at -$71.0 million (up 40.26% YoY), and the FY2025 full-year result was -$93.9 million, up 27.04% from the prior year.
- Free Cash Flow fell to -$20.8 million in Q1 2026, from -$18.7 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $988000.0 in Q3 2025 to a low of -$55.5 million in Q2 2023.
- A 5-year average of -$29.8 million and a median of -$30.2 million in 2024 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow slumped 809.11% in 2024 and surged 105.28% in 2025, its largest moves.
- Tracing AXSM's Free Cash Flow over 5 years: stood at -$27.7 million in 2022, then fell by 9.46% to -$30.4 million in 2023, then rose by 13.62% to -$26.2 million in 2024, then grew by 28.62% to -$18.7 million in 2025, then dropped by 11.2% to -$20.8 million in 2026.
- Business Quant data shows AXSM's Free Cash Flow at -$20.8 million in Q1 2026, -$18.7 million in Q4 2025, and $988000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Axsome Therapeutics | 12.37 Bn | 12.06 Bn | 176.48 Mn | -20.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.82 Mn |
| Mar 31, 2026 | -20.82 Mn |
| Dec 31, 2025 | -18.72 Mn |
| Dec 31, 2025 | -18.72 Mn |
| Sep 30, 2025 | 988,000.00 |
| Sep 30, 2025 | 988,000.00 |
| Jun 30, 2025 | -32.44 Mn |
| Jun 30, 2025 | -32.44 Mn |
| Mar 31, 2025 | -43.71 Mn |
| Mar 31, 2025 | -43.71 Mn |
| Dec 31, 2024 | -26.23 Mn |
| Dec 31, 2024 | -26.23 Mn |
| Sep 30, 2024 | -18.72 Mn |
| Sep 30, 2024 | -18.72 Mn |
| Jun 30, 2024 | -30.16 Mn |
| Jun 30, 2024 | -30.16 Mn |
| Mar 31, 2024 | -53.57 Mn |
| Mar 31, 2024 | -53.57 Mn |
| Dec 31, 2023 | -30.37 Mn |
| Dec 31, 2023 | -30.37 Mn |